Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population

European Journal of Clinical Pharmacology

Volumn 61, Issue 7, 2005, Pages 491-497

  Halling, Jónrit ^a   Petersen, Maria S ^b   Damkier, Per ^c   Nielsen, Flemming ^a,b   Grandjean, Philippe ^b   Weihe, Pál ^d   Lundgren, Stefan ^e   Lundblad, Mia Sandberg ^e   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d FAROESE HOSPITAL SYSTEM   (Faroe Islands)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2C19; CYP2C8; CYP2C9; CYP2D6; Faroe Islands; Polymorphism

Indexed keywords

2,3 DIDEHYDROSPARTEINE; 5,6 DIDEHYDROSPARTEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLITE; DRUG METABOLIZING ENZYME; MEPHENYTOIN; SPARTEINE SULFATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUCASIAN; CONFIDENCE INTERVAL; DEVICE; DRUG METABOLISM; ENZYME ACTIVITY; FAROE ISLANDS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 24044471025     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0938-1     Document Type: Article

References (40)

1. http://www.imm.ki.se/cypalleles
2. Nebert DW, Russel DW (2002) Clinical importance of cytochromes P450. The Lancet 360:1155-1162
3. Wedlund PJ (2000) The CYP2C19 Enzyme Polymorphism. Pharmacology 61:174-183
4. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 29:192-209
5. Alván G, Becthel P, Islius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European population. Eur J Clin Pharmacol 39:533-537
6. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397
7. Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K (1998) Ultrarapid metabolism of sparteine:frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 8:119-123
8. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279(10):9497-9503
9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphism in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607
10. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ (2002) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30(4):385-390
11. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355
12. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, De Faire U, Rane A (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphism. Biochem Biophys Res Commun 299(1):25-28
13. Debes HJ (1990) Føroya Søga 1. Føroya Skúlabókagrunnur, Tórshavn
14. Young GVC (1979) From the Vikings to the reformation: a chronicle of the Faroe Islands up to 1538. Shearwater Press, Onchan, Isles of Man
15. Jorgensen TH, Buttenschon HN, Wang AG, Als TD, Borglum AD, Ewald H (2004) The origin of the isolated population of the Faroe Islands investigated using Y chromosomal markers. Hum Genet 115(1):19-28
16. Jóhansen J (1885) Studies in the vegetational history of the Faroe and Shetlands Islands. Føroya Fródskaparfelag, Tórshavn
17. Jeganathan D, Chodhari R, Meeks M, Færoe O, Smyth D, Nielsen K, Amirav I, Luder AS, Bidgaard H, Gqrdiner RM, Chung EMK, Mitchinson HM (2004) Loci for primary ciliary dyskinesia map to chromosome 16p12.1-12.2 and 15q13.1-15.1 in Faroe Islands and Israeli Druze genetics isolates. J Med Genet 41:233-240
18. Santer R, Kinner M, Steuerwald U, Kjærgaard S, Skovby F, Simonsen H, Shaiu W-L, Chen T-T, Schneppenheim R, Schaub J (2001) Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands. Eur J Hum Gen 9:388-391
19. Milman N, Steig T, Koefoed P, Pedersen P, Fenger K, Nielsen FC (2004) Frequency of the hemochromatosis HFE mutations C282Y, H63D, and S65C in blood donors in the Faroe Islands. Ann Hematol 84(3):146-149
20. Schwartz M, Sorensen N, Brandt NJ, Hogdall E, Holm T (1995) High incidence of cystic fibrosis on the Faroe Islands: a molecular and genealogical study. Hum Genet 95(6):703-706
21. Hjalgrim H, Tulinius H, Dalberg J, Hardarson S, Frisch M, Melbye M (1998) High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands. Br J Cancer 77(7):1190-1193
22. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62(4):365-376
23. Damkier P, Hansen LL, Brosen K (1999) Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 48(6):829-838
24. Vinks A, Inaba T, Otton SV, Kalow W (1982) Sparteine metabolism in Canadian Causcasians. Clin Pharmacol Ther 31:23-29
25. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA (1984) Wilkinson GR. Direct enantionmeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatogram. J Chromatogr 13(307):121-127
26. Sanz EJ, Villén T, Alm C, Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisquine. Clin Pharmacol Ther 45:495-499
27. Tybring G, Bertilsson L (1992) A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 2:241-243
28. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer US, Nakamura K, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Bio Chem 269:15419-15422
29. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer US, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
30. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E (2004) The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32(5):484-489
31. McCann SJ, Pond SM, James KM, Le Couteur DG (1997) The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 153(1):50-53
32. Christensen PM, Gotzsche PC, Brosen K (1998) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics 8(6):473-479
33. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA (1995) The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 10(5):541-549
34. Gudmundsson KR (1967) A clinical survey of parkinsonism in Iceland. Acta Neurol Scand 43(Suppl 33):1-61
35. Wermuth L, Joensen P, Bunger N, Jeune B (1997) High prevalence of Parkinson's disease in the Faroe Islands. Neurology 49(2):426-432
36. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 46(3):377-394
37. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53(2):111-122
38. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, Henauer S, Jackson P, Laux G, Mikkelsen H, Peck C, Pollock BG, Priest R, Sjoqvist F, Delini-Stula A (1996) Antidepressants and drug-metabolizing enzymes-expert group report. Acta Psychiatr Scand 93(2):71-79
39. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, Stuber F (2003) Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105(1-2):231-238
40. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60(6):636-644